PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.
People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.
Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.
User discusses trying Low Level Laser Therapy (LLLT) for hair loss and its high cost. Another user shares their experience combining micro needling, minoxidil, and LLLT, seeing positive results after 2 months.
Low-level laser therapy (LLLT) stimulates hair growth but current devices are expensive. A proposed non-profit project aims to create affordable, 3D-printed LLLT devices and collect data on their effectiveness.
PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.
PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.
PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.
Results for PP405 are expected next year, with concerns about its pricing and potential black market availability. Some users believe it may be slightly more effective than finasteride and dutasteride, and combining it with treatments like minoxidil and microneedling could be beneficial.
Red light therapy for hair loss is controversial, with mixed results reported. Its effectiveness may depend on device quality and proper wavelength, and it is often used with minoxidil and finasteride.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.
Low-Level Laser Therapy (LLLT) for hair loss is effective but requires consistent use and device replacement every 1-2 years. The treatment is costly, and results may not be permanent without continued use.
The conversation is about the effectiveness of low-level laser therapy (LLLT) caps for hair regrowth. One user suggests saving money, implying LLLT caps may not be beneficial.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
The conversation discusses concerns about the effectiveness of RU58841 due to high temperatures during delivery. A user reassures that the heat will not affect its efficacy.
PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.
The conversation is about the lack of discussion on Low-level laser light therapy (LLLT) laser caps for hair loss. One user questions their effectiveness, and another asserts they don't work.
PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.
People are discussing the use of an untested hair loss treatment called PP405, which is not available on the grey market. Some users are trying a mimic formulation called HP3, reporting thicker hair but no new growth yet.
Low-Level Laser Therapy (LLLT) is considered expensive and may not provide significant benefits, with some users suggesting alternatives like finasteride, minoxidil, and microneedling. Many users report limited success with LLLT and similar treatments, recommending more proven options instead.
Finasteride has shown great results for hair loss. The discussion also inquires about the effectiveness and side effects of Low-Level Laser/Light Therapy (LLLT).
The conversation discusses using a violet ray device for hair regrowth, citing a case where zinc ion treatments showed promising results. It also mentions similar devices like the Growcombr and niostem helmet.
PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.